Q-omics provides the consensus-scored GAPDHS profile across patient tissues and cancer cell-line models. GAPDHS expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, GAPDHS is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, GAPDHS RNA expression shows 10,571 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight DLBC, HNSC, and LSCC as cancer lineages where GAPDHS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHS survival associations across molecular data types. GAPDHS RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHS RNA expression–survival associations across cancer types. High GAPDHS expression shows unfavorable associations in DLBC, KIRC, KIRP, ACC and THCA, but favorable associations in SCLC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for GAPDHS RNA expression.
This table summarizes GAPDHS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GAPDHS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHS shows lower tumor expression in HNSC and higher tumor expression in LUSC, BLCA, CHOL, COAD and LUAD. The HNSC box plot shows higher GAPDHS RNA expression in normal versus tumor tissue (log2 FC = −0.118, t-test p = .021).
This table shows molecular features associated with GAPDHS in patient tissues and cancer cell lines. In patient samples, GAPDHS shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GAPDHS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
